Research & Innovation

We are at the forefront in the field of probiotics and human health

Colon Cancer Studies

Recently scientists have performed a colon cancer study, where patients were given lactobacilli and bifidobacteria. This study was published in the British Medical Journal (BMJ Open Gastro) July 2017.

Results: “ProBion clinica given to colon cancer patients reduces more than 90% of cancer related microbes”.

ProBion Matrix

Innovative production technique efficiently delivers, feeds and protects vigorous and non-damaged bacteria in the gastrointestinal tract for extended periods of time.

Makes it possible to use all kinds of lactobacilli or bifidobacteria strains in further research.

Honest Science

We are at the forefront in the field of probiotics and human health.

Developed by Wasa Medicals AB in Sweden, ProBion dry tablets were used in recent human clinical study aimed at ascertaining effect of probiotics on gut bacteria in colon cancer patients. It has been found that two tablets of ProBion Clinica a day for an average of 31 days had wiped out a significant amount of cancer associated harmful bacteria and generated a plethora of beneficial bacteria with anti-inflammatory effects. It showed promise in using probiotics to mitigate dysbiosis and improve gut health for cancer prevention. It also showed that ProBion tablets delivered undamaged probiotic bacteria in the large intestines to achieve therapeutic effect. The study was conducted by scientists at the Sahlgrenska University Hospital in Gothenburg. Results published in July 2017 in BMJ Journal, a leading open access platform for scientific papers specialising in gastroenterology.

Wasa Medicals AB, based in Halmstad, Sweden, is a member of the International Probiotic Association (IPA). Led by CEO Lennart Cedgard, MD, the company developed the ProBion dry tablet matrix through collaboration with Swedish doctors and scientists, and has continuously researched probiotic dosage effect for 25 years. Mr Cedgard has over 35 years clinical experience in intestinal microecology and is contributor of papers on probiotics and microbiology to medical journals. In 2016 he co-founded ProBion Innovation Sweden AB (PISA), a biotechnology research company, to study innovative use of probiotics for alleviating diseases.